A Study of BAX 888 in Male Adults With Severe Hemophilia A

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

February 27, 2018

Primary Completion Date

July 9, 2024

Study Completion Date

July 9, 2024

Conditions
Hemophilia A
Interventions
DRUG

BAX 888

Participants will receive a single peripheral IV infusion of BAX 888 in Cohort 1 and 2 Day 0.

Trial Locations (26)

1083

Semmelweis Egyetem, Budapest

1090

AKH - Medizinische Universität Wien, Vienna

10029

Mount Sinai Medical Center, New York

10249

Vivantes Klinikum im Friedrichshain, Berlin

13385

Hôpital de la Timone, Marseille

28046

Hospital Universitario La Paz, Madrid

29010

Hospital Regional Universitario de Malaga, Málaga

29425

Medical University of South Carolina (MUSC), Charleston

29609

Hôpital Morvan, Brest

35000

CHU Rennes - Hopital Pontchaillou, Rennes

37007

Hospital Clinico Universitario de Salamanca, Salamanca

37044

CHU Tours - Hôpital Trousseau, Tours

44093

CHU de Nantes Site Hotel Dieu, Nantes

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

46026

Hospital Universitari i Politecnic La Fe, Valencia

59037

Hopital Jeanne de Flandre - CHU Lille, Lille

60590

Klinikum der Johann Wolfgang Goethe-Universitaet, Frankfurt am Main

69677

Groupement Hospitalier Est- Hôpital Louis Pradel, Bron

80045

University of Colorado Hemophilia & Thrombosis Center, Aurora

85016

Phoenix Childrens Hospital, Phoenix

90007

Orthopaedic Hospital DBA Orthopaedic Hemophilia Treatment Center, Los Angeles

94275

Hôpital Bicêtre, Le Kremlin-Bicêtre

95817

UC Davis Medical Center, Sacramento

77030-4009

Gulf States Hemophilia and Thrombophilia Center, Houston

01307

Universitaetsklinikum Carl Gustav Carus TU Dresden, Dresden

08035

Hospital Universitari Vall d'Hebron, Barcelona

All Listed Sponsors
collaborator

Baxalta Innovations GmbH, now part of Shire

INDUSTRY

collaborator

Takeda Development Center Americas, Inc.

INDUSTRY

lead

Baxalta now part of Shire

INDUSTRY

NCT03370172 - A Study of BAX 888 in Male Adults With Severe Hemophilia A | Biotech Hunter | Biotech Hunter